Role of microRNAs in Non-Alcoholic Steatohepatitis

被引:22
|
作者
Cheung, Onpan [1 ]
Sanyal, Arun J. [1 ]
机构
[1] Virginia Commonwealth Univ, Div Gastroenterol Hepatol & Nutr, Dept Internal Med, Med Ctr, Richmond, VA 23298 USA
关键词
microRNA; non-alcoholic steatohepatitis; non-alcoholic fatty liver disease; insulin resistance; metabolic syndrome; UNFOLDED PROTEIN RESPONSE; HEPATIC LIPOGENESIS; CARDIOVASCULAR RISK; IN-VIVO; GENE; ACTIVATION; OBESITY; ACID; DYSREGULATION; METABOLISM;
D O I
10.2174/138161210791208866
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is not entirely understood. Recently, the role of microRNA in this liver disease entity and its implication in disease pathogenesis and therapeutic potential has advanced rapidly over the year. While the regulation of miRNA function and its mechanism of actions on translational control of target mRNA expression remain unknown, advances in miRNA research allow identification and biochemical characterization of events that limit protein expression, which is crucial in various forms of human diseases and their subsequent development. It is hoped that further understanding of the role of microRNA in NAFLD will advance potential therapeutics and preventive measures to modify and alter this disease process.
引用
收藏
页码:1952 / 1957
页数:6
相关论文
共 50 条
  • [41] Liver fibrogenesis in non-alcoholic steatohepatitis
    Bian, Zhaolian
    Ma, Xiong
    FRONTIERS IN PHYSIOLOGY, 2012, 3
  • [42] PORPHIRIN METABOLISM IN NON-ALCOHOLIC STEATOHEPATITIS
    Krivosheev, A. B.
    Kuimov, A. D.
    Morozov, D. V.
    Krivosheeva, I. A.
    Gmyza, O. A.
    TERAPEVTICHESKII ARKHIV, 2008, 80 (11) : 64 - 68
  • [43] Emerging drugs for non-alcoholic steatohepatitis
    Tomeno, Wataru
    Yoneda, Masato
    Imajo, Kento
    Ogawa, Yuji
    Kessoku, Takaomi
    Saito, Satoru
    Eguchi, Yuichiro
    Nakajima, Atsushi
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (03) : 279 - 290
  • [44] Non-alcoholic steatohepatitis and liver transplantation
    Gitto, Stefano
    Vukotic, Ranka
    Vitale, Giovanni
    Pirillo, Martina
    Villa, Erica
    Andreone, Pietro
    DIGESTIVE AND LIVER DISEASE, 2016, 48 (06) : 587 - 591
  • [45] Evaluation and management of non-alcoholic steatohepatitis
    Reid, BM
    Sanyal, AJ
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (11) : 1117 - 1122
  • [46] CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Sila Cocciolillo
    Giustino Parruti
    Leonardo Marzio
    World Journal of Hepatology, 2014, (07) : 496 - 503
  • [47] Non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic Steatohepatitis (NASH): Pathophysiology and Nutritional Aspects
    Schattenberg, Joern M.
    ERNAHRUNGS UMSCHAU, 2015, 62 (02): : M92 - M100
  • [48] Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Senavirathna, Tharani
    Shafaei, Armaghan
    Lareu, Ricky
    Balmer, Lois
    ANTIOXIDANTS, 2024, 13 (04)
  • [49] CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Cocciolillo, Sila
    Parruti, Giustino
    Marzio, Leonardo
    WORLD JOURNAL OF HEPATOLOGY, 2014, 6 (07) : 496 - 503
  • [50] Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review
    Eguchi, Yuichiro
    Wong, Gabriel
    Lee, Emma
    Akhtar, Omar
    Lopes, Ricardo
    Sumida, Yoshio
    JGH OPEN, 2020, 4 (05): : 808 - 817